Výsledky vyhledávání - "Albert Candia"

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Autor: Amy L. Cummings, Lyudmila Bazhenova, Edward B. Garon, Melissa Lynne Johnson, Alexander I. Spira, Joseph Leach, Mary J. Janatpour, Robert L. Coffman, Laura Q.M. Chow, Erick Gamelin, Albert Candia, Robert Janssen

Publikováno v: Clinical Cancer Research. 27:4566-4573

Purpose: Although PD-(L)1 inhibitors have shown efficacy in advanced/metastatic non–small cell lung cancer (NSCLC), many patients do not respond to this treatment and more effective combinations with acceptable toxicities are needed. To assess the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e7cd238ce472904696326bf7365e55
https://doi.org/10.1158/1078-0432.ccr-21-0263

Zobrazit plný text záznamu

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Autor: Antoni Ribas, Shivaani Kummar, Theresa Medina, Emmett V. Schmidt, Gregory A. Daniels, Robert Janssen, Minal A. Barve, Anusha Kalbasi, Robert L. Coffman, Asim Amin, Abraham C.F. Leung, Albert Candia, Joseph J. Drabick, Deborah J. Wong

Publikováno v: Cancer discovery, vol 8, iss 10

PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03838030bb6dde39ddb84d827a33daa
https://escholarship.org/uc/item/8fx0m626

Zobrazit plný text záznamu

In situ vaccination with a TLR 9 agonist and local low dose radiation induces systemic responses in untreated indolent lymphoma

Autor: Steven R. Long, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Patrick M. Reagan, Richard T. Hoppe, Nancy L. Bartlett, Albert Candia, Matthew J. Frank, Ronald Levy, Robert Janssen, Robert L. Coffman

This multicenter phase I/II clinical trial evaluated intratumoral SD-101, a TLR9 agonist, and low-dose radiation in patients with untreated indolent lymphoma. Twenty-nine enrolled patients received 4 Gy of radiation followed by 5 weekly intratumoral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd627106ac9b6a6758afb8aff7a08c71
https://europepmc.org/articles/PMC6171524/

Zobrazit plný text záznamu

Small-Molecule TLR8 Antagonists via Structure-Based Rational Design

Autor: Umeharu Ohto, Toshiyuki Shimizu, Kyoin Koo, Kentaro Sakaniwa, H. Tanji, Zhenyi Hu, Shuangshuang Jiang, Hang Yin, Albert Candia, Shuting Zhang, Jean Chan

Publikováno v: Cell chemical biology. 25(10)

Rational design of drug-like small-molecule ligands based on structural information of proteins remains a significant challenge in chemical biology. In particular, designs targeting protein-protein interfaces have met little success given the dynamic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20246ed8095415ff0caddef6b9dc4986
https://pubmed.ncbi.nlm.nih.gov/30100350

Zobrazit plný text záznamu

First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated

Autor: Clifford Wong, Albert Candia, Sariah A. Kell, Ian Robinson, Simone Floettmann, Jeremy A. Lum, John D. Campbell, Edith M. Hessel, Mark McHale, Stephen Delaney, Rainard Fuhr, John Bell, Sam Jackson, David J. Keeling, Paula Traquina, Robert L. Coffman

Publikováno v: Clinical pharmacology and therapeutics. 104(2)

Current asthma treatments address symptoms rather than the underlying disease pathophysiology, a better understanding of which has led to the identification of the Th2 high endotype. The activation of Toll-like receptors to induce Type I interferons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f197798ab957f6543d70e5bb0feb44c3
https://pubmed.ncbi.nlm.nih.gov/29134633

Zobrazit plný text záznamu

Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC)

Autor: Lyudmila Bazhenova, Edward B. Garon, Erick Gamelin, Robert L. Coffman, Alexander I. Spira, Robert Janssen, Laura Q.M. Chow, Albert Candia, Melissa Lynne Johnson, Mary J. Janatpour, Joseph Leach

Publikováno v: Cancer Research. 79:CT224-CT224

Background and Objectives: DV281 is a synthetic CpG-ODN agonist of TLR9 that stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells to activate T cell anti-tumor responses. Nivolumab is a PD-1 inhibitor that has demo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcae5b5014830cb46e0f3d0698878503
https://doi.org/10.1158/1538-7445.am2019-ct224

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání